Key Takeaways: Embecta Corp. faces a securities class action after its shares plunged 57.8 percent to $3.90 on May 5, 2026, following a guidance cut. The lawsuit alleges the company misled investors about its pen needle business and fiscal year 2026 revenue guidance. Investors have until Aug. 17, 2026 to seek lead plaintiff appointment.
Embecta Corp. faces a securities class action after its shares plunged 57.8 percent to $3.90 on May 5, 2026, following a guidance cut.
"The case presents important questions about revenue guidance disclosure obligations in the medical device sector," Joseph E. Levi, founding partner at Levi & Korsinsky LLP, said.
The lawsuit, filed in the U.S. District Court for the District of New Jersey, alleges Embecta misled investors about the strength of its pen needle business and fiscal year 2026 revenue guidance between Nov. 25, 2025 and May 4, 2026. Embecta cut its FY2026 revenue guidance by about 46 percent and reduced its quarterly dividend 93 percent to $0.01 from $0.15. Pen needles and safety pen needles represent about 85 percent of the company's product portfolio.
The stock fell $5.35 per share, or 57.8 percent, from $9.25 on May 4 to $3.90 on May 5. Investors who purchased Embecta securities during the class period have until Aug. 17, 2026 to seek appointment as lead plaintiff.
The complaint, captioned Apitz-Grossman v. Embecta Corp., No. 26-cv-07217, asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. It alleges Embecta repeatedly reaffirmed FY2026 revenue guidance of $1.071 billion to $1.093 billion while facing accelerating share loss in its pen needle segment. Pen needle shortfalls accounted for roughly $53 million of the $75 million total guidance reduction, or more than 70 percent of the miss.
The complaint details additional headwinds: market volume softness in the retail channel for insulin pens and pen needles contributed an estimated $20 million shortfall, while inventory reductions and net pricing pressure added about $8 million. Syringe, swab and safety product declines contributed another $22 million, including $13 million from syringes, $5 million from discontinued swab products and $4 million from safety products. Share loss was concentrated at a single major customer, which the company described as "incredibly resolute" weeks before the miss.
The insulin delivery device market has been shifting as pump adoption and GLP-1 therapies reshape patient purchasing patterns in the United States. Embecta cited geographic diversification and the stability of insulin pen prescriptions to reassure investors, while the U.S. retail channel was already seeing declines in new insulin pen prescriptions, the complaint alleges.
Robbins LLP and Bleichmar Fonti & Auld LLP have also announced the class action, which is being handled on a contingency basis. The legal overhang adds pressure to a stock already trading near its lowest levels, and a settlement or adverse ruling could weigh further on Embecta's valuation. Investors will watch the lead plaintiff deadline on Aug. 17, 2026 and any subsequent court rulings for the case's trajectory.
This article is for informational purposes only and does not constitute investment advice.
